A cash infusion from Nestle and an uptick in online consumer sales has buoyed ChromaDex as executives say the brand is on course to be in plus EBITDA territory by the end of fiscal 2022.
America’s nicotinamide riboside (NR) maker Chromadex is eyeing omnichannel retail in China and is confident of achieving the ‘blue-hat’ health foods registration status – required for normal trade of health foods in China – in the next 24 months or less....
China’s consumers are increasingly aware of how nicotinamide adenine dinucleotide (NAD+) plays a role in health, and Chromadex believes this presents opportunities for its flagship product Tru Niagen.
ChromaDex has launched its nicotinamide riboside (NR) supplement, TRU NIAGEN, in stick packs in Hong Kong as it seeks to cater to the nutritional needs of active individuals, beyond its traditional healthy ageing customer base.
Chromadex, the nicotinamide riboside (NR) specialist, has entered the beauty-from-within space with its new product exclusively launched in A.S. Watsons Hong Kong both offline and online.
ChromaDex has received approval from the Australian Therapeutic Goods Administration (TGA) for use of its patented nicotinamide ribosome chloride (NR) in listed complementary medicines in the country.
Personalised nutrition and other specific therapeutic functions with a focus on changing the concept of ageing are the way forward for ChromaDex’s flagship nicotinamide riboside (NR) supplement, said the firm.
A shift in market dynamics — not a legal dispute with a key customer — is what drove ChromaDex to try for a second time the finished products route for one of its branded ingredients.
